MichaelVincentRobersMDMS

Neurology • Phoenix, AZ

Neuroimmunology/Multiple Sclerosis

Assistant Professor of Neurology Barrow Neurological Institute

Join to view full profile

Dr. Robers is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Robers' full profile

Already have an account?

Office
240 W Thomas Rd
Suite 400
Phoenix, AZ 85013
Phone+1 602-406-6262

Education & Training

University of Southern California/LAC+USC Medical CenterFellowship, Neuroimmunology & Multiple Sclerosis, 2018 - 2020
Barrow Neurological Institute at St Joseph's Hospital and Medical CenterChief Residency, Neurology, 2017 - 2018
Barrow Neurological Institute at St Joseph's Hospital and Medical CenterResidency, Neurology, 2014 - 2018
Creighton University School of Medicine/St Joseph's Medical Center (Phoenix)Internship, Transitional Year, 2014 - 2015
Loyola University Chicago Stritch School of MedicineClass of 2014

Certifications & Licensure

AZ State Medical License 2020 - 2025
CA State Medical License 2018 - 2022
American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

Adult Neurology Teacher of the Year Barrow Neurlogical Institute, 2024
Quality and Safety Award American Academy of Neurology, 2018

Clinical Trials

A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis Start of enrollment: 2011 Mar 02
Completed
Phase 3
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone Start of enrollment: 2012 Aug 09
Terminated
Phase 3
Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409 Start of enrollment: 2015 Jan 07
Completed
Phase 4
Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS) Start of enrollment: 2014 Dec 03
Completed
Phase 3
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT) Start of enrollment: 2016 Feb 11
Completed
Phase 3
Assessment of Tecfidera® in Radiologically Isolated Syndrome (RIS) Start of enrollment: 2016 Mar 19
Completed
Phase 4
Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis Start of enrollment: 2016 Sep 20
Completed
Phase 3
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2) Start of enrollment: 2016 Dec 01
Terminated
Phase 3
Join now to see all

Publications & Presentations

PubMed

Current opinion: Racial and ethnic health disparities in multiple sclerosis: considering the social determinants of health.
Michael V Robers, Lilyana Amezcua
Current Opinion in Neurology. 2024-06-01
3 citations
Inclusion of optic neuritis in dissemination in space improves the performance of McDonald 2017 criteria in Hispanic people with suspected multiple sclerosis.
Lilyana Amezcua, Michael V Robers, Deepak Soneji, Olga Manouvakhova, Andrea Martinez
Multiple Sclerosis. 2023-12-01
5 citations
Multiple sclerosis in Indigenous Peoples of the Americas: A systematic review of incidence, prevalence, and outcomes.
Michael V Robers, Brigitte Hurtubise, Melissa H Roberts, Rheanna Robinson, Hollie Schmidt
Multiple Sclerosis and Related Disorders. 2023-04-01

Journal Articles

Internuclear Opthalmoplegia Characterizes Multiple Sclerosis Rather than Neuromyelitis Optica Spectrum Disease
Mahmoud M. Hamza, Basher F. Alas, Connie Huang, Justin C. Quon, Lilyana Amezcua, Michael V. Robers, Kimberly K. Gokoffski, Journal of Neuro-Ophthalmology, 3/25/2022

Grant Support

Sylvia Lowery Physician FellowshipNational Multiple Sclerosis Society2018–2020

Professional Memberships

American Academy of Neurology - AAN
Member